Biofrontera AG (B8FK) NPV
€0.015
(0.68%)
- Add to watchlist
- This stock can be held in a
€0.015
(0.68%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
€0.015
(0.68%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Contact details
Important dates
General stock information
- Short code:
- B8FK
- ISIN:
- DE000A4BGGM7
- Market cap:
- €14.89 million
- Shares in issue:
- 6.08 million
- Sector:
- Pharmaceuticals
- Exchange:
- Frankfurt Stock Exchange
- Country:
- Germany
- Currency:
- Euro
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.